News : Inclinix

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.
During the first quarter Diamyd Medical has reported several important events that have contributed positively to the Company’s development. The financial position has been...

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd®.
Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd®, including in total 640 children and adolescents with...

Diamyd Medical reported today that from September 1, children from 10 years of age with type 1 diabetes will be included in the company’s US Phase III study of the Diamyd® diabetes vaccine. The company is also trebling the number of clinics and is investing in expanded recruitment activities in the US.
Diamyd Medical’s Phase III study of the Diamyd® diabetes vaccine in the US has so far only been open to...